CF Flashcards
CF incidence
1 in 3,000
CF inheritance pattern
autosomal recessive
CFTR mutation
on chromosome 7
most common mutation in CF
F508del
mechanism of CF
CFTR channels absent or reduced
CFTR not properly transporting Cl
screening in newborns for CF
IRT test to see if genes present
diagnosis of CF
symptom and presence of CFTR dysfunct
sweat chloride test >60
also genetic and pancreatic testing
class I mutations
X
CFTR not there
class II mutations
F508del
little to no CFTR, the CFTR there does not properly transport Cl
class III mutations
G551D
normal number of CFTR, Cl not transported properly
class IV mutations
R
normal number of CFTR, some Cl transported properly
class V mutations
G to A
reduced number of CFTR but it transports properly
CFTR modulator drugs
Kalydeco (ivacaftor)
Orkambi (ivacaftor, lumacaftor)
Symdeko (ivacaftor, tezacaftor)
Trikafta (ivacaftor, tezacaftor, elaxacaftor)
Alyftrek (vanzacaftor, texacaftor, deutivacaftor)
Kalydeco (ivacaftor) age range
> 1 month
Kalydeco (ivacaftor) mechanism
potentiator, helps open door so Cl can flow through
(class III, IV)
Kalydeco (ivacaftor) counseling
take w fatty foods
interaction w grapefruit jucie and 3A4s
Kalydeco (ivacaftor) approved for what
responsive mutations
Kalydeco (ivacaftor) monitoring considerations
LFTs every 3 months for 1 year then yearly
eye exam baseline and yearly (peds)
dose adjust for hepatic impairment
Orkambi (ivacaftor/lumacaftor) age
> 1 month
Orkambi (ivacaftor/lumacaftor) indication
F508del homozygous mutation
Orkambi (ivacaftor/lumacaftor) counseling
take with fatty foods
birth control drug interaction
lumacaftor 3A4 inducer
Orkambi (ivacaftor/lumacaftor) side effect
chest tightness and SOB
Orkambi (ivacaftor/lumacaftor) monitoring
AST/ALT/bili every 3 months for 1 year then yearly
eye exam baseline and yearly
dose adjust hepatic impairment
Symdeko (ivacaftor/tezacaftor) age
> 6 years
Symdeko (ivacaftor/tezacaftor) counseling
take with fatty foods
iva CYP3A4